---
title: "Analysts highlight top mid-cap growth plays with low valuations"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/288935629.md"
description: "Analysts identify mid-cap stocks offering a blend of strong growth and low valuations. Key highlights include American Superconductor and TG Therapeutics as top picks. Globus Medical and RB Global demonstrated robust revenue and earnings growth, whereas DocuSign faces challenges with slower ARR expansion. The recommended investments span diverse sectors such as biotech, REITs, financials, aerospace, and semiconductors, providing investors with varied opportunities for balanced growth."
datetime: "2026-06-06T15:33:38.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/288935629.md)
  - [en](https://longbridge.com/en/news/288935629.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/288935629.md)
---

# Analysts highlight top mid-cap growth plays with low valuations

Growth meets value: Mid-cap firms across sectors show strong growth metrics while trading at modest valuations, led by American Superconductor and TG Therapeutics. Winners and a warning: Globus Medical and RB Global post standout revenue and earnings growth, while DocuSign faces slower ARR expansion and customer acquisition challenges. Sector-wide diversity: Top picks span biotech, REITs, financials, aerospace, and semiconductors, offering varied exposure for investors seeking balanced growth opportunities.

### Related Stocks

- [RBA.US](https://longbridge.com/en/quote/RBA.US.md)
- [GMED.US](https://longbridge.com/en/quote/GMED.US.md)
- [TGTX.US](https://longbridge.com/en/quote/TGTX.US.md)
- [AMSC.US](https://longbridge.com/en/quote/AMSC.US.md)
- [DOCU.US](https://longbridge.com/en/quote/DOCU.US.md)

## Related News & Research

- [Docusign: Another Beat, Another Selloff—Why the Analysts Are Wrong](https://longbridge.com/en/news/289058792.md)
- [Docusign dips after Q1 results, analysts mull ARR growth outlook, IAM platform](https://longbridge.com/en/news/288859773.md)
- [DocuSign’s Growing Risk Exposure: How Evolving Operational, Regulatory, and Market Threats Could Pressure Growth and Earnings](https://longbridge.com/en/news/288952318.md)
- [BUZZ-TG Therapeutics rises as early-stage data shows benefit in rare muscle weakness disease](https://longbridge.com/en/news/289184641.md)
- [DocuSign stock falls as cautious outlook overshadows earnings beat](https://longbridge.com/en/news/288887867.md)